- Home
- PWRL vs GYRE Comparison
PWRL vs GYRE Comparison
Compare PWRL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PWRL | GYRE |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.6M | 606.4M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | PWRL | GYRE |
|---|---|---|
| Price | $12.10 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 121.0K | 60.8K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.84 | $5.44 |
| 52 Week High | $16.31 | $9.42 |
Technical Indicators
Market Signals| Indicator | PWRL | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 43.36 |
| Support Level | N/A | $5.78 |
| Resistance Level | $13.39 | $8.28 |
| Average True Range (ATR) | 0.85 | 0.27 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 12.13 | 15.18 |
Price Performance
Historical ComparisonAbout PWRL Powerlaw Corp. Common Stock
Powerlaw Corp is a non-diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation. It seeks to achieve its investment objective by investing in the equity and equity-linked securities of a concentrated portfolio of approximately 12 to 15 late-stage technology companies.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.